Crown Bioscience Announces New Preclinical and Translational Oncology Data Across Ten Poster Presentations at AACR 2024
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting. Highlighting its latest research, the company will present ten posters covering a broad spectrum of data from the company's R&D program.
The data presented will cover a range of innovative techniques in oncology and immuno-oncology drug discovery and development. Posters featured at AACR include:
- The in-depth Characterization of Acute Myeloid Leukemia Patient-Derived Xenograft (PDX) Models with Hotspot Gene Mutations for Therapeutic Evaluation.
- The development of an Integrated Pipeline for Immuno-Oncology Drug Testing, using patient-derived tumor organoids with a reconstituted tumor microenvironment and fresh ex vivo patient tissue cultures, aiming to enhance therapeutic evaluation and drug development efficiency with translational patient-derived systems.
- The utilization of Large Panel Organoid Drug Testing Combined with Biomarker Analysis, set to deliver insights into mechanisms of action and boost efficiency within the drug development pipeline.
- Research on KRAS Inhibitors and PARP Inhibitor-Induced Resistant PDX Ovarian Cancer Models further expands on the knowledge base of drug resistance patterns in cancer while also assessing innovative therapeutic approaches for targeting mutated tumors, including combination therapy.
- SynAI, an adaptive AI-driven platform for in silico drug synergism screening, optimizes the exploration of compound interactions in early-stage cancer drug development.
- Magnetic Resonance Imaging and Bioluminescence Imaging for Evaluating Tumor Burden in Orthotopic Glioblastoma, merging digital technology with cancer research to forecast a new era of therapeutic strategy development.
Abstracts for all ten poster presentations can be found on a dedicated page, Crown Bioscience AACR posters 2024. Following the show, all will be available for download.
Attendees are encouraged to visit Booth #1717 to learn more about these studies and talk to Crown Bioscience’s scientists to gain deeper insights into the platforms and services on offer to advance oncology research.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) partnering with biotech and pharmaceutical companies to rapidly advance the discovery and development of oncology drugs. As the exclusive preclinical CRO providing tumor organoid services with the well-established Hubrecht Organoid Technology, we offer over 600 organoid models spanning 22 cancer indications. Furthermore, we have developed the world’s largest commercially available PDX collection. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 13 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328082232/en/
Contact information
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QPS Celebrates 30 th Anniversary4.6.2025 19:00:00 EEST | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604778675/en/ Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a globa
Cessna SkyCourier Combi Configuration Achieves Certification From the National Civil Aviation Agency of Brazil4.6.2025 18:30:00 EEST | Press release
The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604928791/en/ The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. (Photo credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. CTA recently took delivery of a passenger variant of the twin-engine, large-utility turboprop equipped with conversion kits that enable the standard 19-passenger interior
IFF Unveils Game-Changing Outlook on GLP-1 Consumers4.6.2025 18:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The report outlines how food and beverage manufacturers can better support this emerging consumer segment with products that align with their evolving preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604818126/en/ “IFF is empowering our customers to lead the next wave of food and beverage innovations beyond traditional formulations, including helping GLP-1 consumers have choices they desire,” said Erik Fyrwald, IFF CEO. “We aim to bring back the joy of eating and drinking by offering more healthy, great-tasting nutrition choices for all consumer segments, including GLP-1 users.” Disconnect on three levels Despite the rapid rise in GLP-1 medication use, most f
Visa Cash App Racing Bulls (VCARB) Formula One™ Team Accelerates Racing Car Design with Neural Concept’s Engineering AI4.6.2025 17:04:00 EEST | Press release
Visa Cash App Racing Bulls Formula One™Team has deployed Neural Concept, the world’s leading AI platform for engineering design to accelerate the team’s car design and optimize aerodynamic performance through AI-powered, data-driven engineering workflows that enable faster design iteration and better-informed decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603592297/en/ Visa Cash App Red Bull - Racing Bulls and Neural Concept AI F1 vehicle partnership Neural Concept’s proprietary Engineering AI platform complements traditional Computational Fluid Dynamics (CFD) with high-speed predictive simulations. Engineers can use digital twins to evaluate thousands of design variants across complex “multi-physics” environments that mimic real-world track conditions such as wind and temperature differences. This enables VCARB to explore more designs, unlocking new performance gains within every iteration. Laurent Mekies, Tea
Money20/20 Europe Hosts Regulators' Closed-Door Roundtable to Accelerate Fintech Innovation4.6.2025 16:51:00 EEST | Press release
Money20/20, the world’s leading fintech show, and the place where money does business, hosted its Policy Exchange on June 3rd at Money20/20 Europe at the RAI in Amsterdam. Money20/20 Europe's Policy Exchange convened senior leaders from central banks, regulatory bodies, and industry to address three critical areas: post-MiCA crypto regulation, financial data access through Open Finance, and cross-border policy in collaboration with BIS. The exclusive closed-door event featured keynote addresses from Suzy Pallett, Executive Vice President of Money20/20 Europe and Gijs Boudewijn, incoming Chair Elect of the European Payments Council, followed by specialized roundtables that highlighted the need for harmonized regulations supporting innovation, security, and global cooperation. "Money20/20 Europe serves as an essential platform where regulators can gather for productive and future-focused discussions in a neutral environment," explained Suzy Pallett, Executive Vice President at, Money20/2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom